Biosimilar Pegfilgrastim-cbqv Demonstrated Similar Immunogenicity to Pegfilgrastim in Healthy Subjects Across Three Randomized Clinical Studies

INTRODUCTION: Biologic therapeutics can trigger immune responses in patients. As part of the totality of evidence that is required for regulatory approval of biosimilars, immunogenicity similarity must be assessed in the clinical programs. Pegfilgrastim-cbqv (UDENYCA(®)) is a pegfilgrastim biosimila...

Descripción completa

Detalles Bibliográficos
Autores principales: Civoli, Francesca, Finck, Barbara, Tang, Helen, Hodge, Jennifer, O’Kelly, Hillary, Vexler, Vladimir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918144/
https://www.ncbi.nlm.nih.gov/pubmed/35034311
http://dx.doi.org/10.1007/s12325-021-02024-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918144/
https://www.ncbi.nlm.nih.gov/pubmed/35034311
http://dx.doi.org/10.1007/s12325-021-02024-x

Ejemplares similares